MARC Affirms Sunway Healthcare AA Ratings On Its RM5 Billion Sukuk
MARC Affirms Sunway Healthcare AA Ratings On Its RM5 Billion Sukuk
MARC Ratings has affirmed its rating of AAIS(cg) on Sunway Healthcare Treasury Sdn Bhd's (SH Treasury) Islamic Medium-Term Notes (Sukuk Wakalah) Programme of up to RM5.0 billion with a Stable outloo.
MARC评级已确认对Sunway Healthcare Treasury Sdn Bhd(SH Treasury)的伊斯兰中期票据(Sukuk Wakalah)计划的AAIS(cg)评级,额度高达50亿马币,前景稳定。
The agency said the rating reflects the credit strength of parent Sunway Healthcare Holdings Sdn Bhd (SHH), based on SHH's unconditional and irrevocable guarantee on the programme.
该机构表示,这一评级反映了母公司Sunway Healthcare Holdings Sdn Bhd(SHH)的信用实力,基于SHH对该计划的无条件和不可撤销的担保。
The affirmed rating reflects SHH's strengthening business profile with a growing market share in the Malaysian healthcare sector and strong debt service ability given its robust internal cash flow generation. SHH's healthy liquidity position and strong financial flexibility supported by a strong ownership profile are also key rating factors. These factors are tempered by execution risk associated with the group's rapid expansion plans, its exposure to regulatory and contingent liabilities, and concerns over the industry-wide shortage of nurses.
确认的评级反映了SHH日益增强的业务形象,在马来西亚医疗行业中市场份额不断增长,且考虑到其强劲的内部现金流生成能力,债务服务能力强。SHH良好的流动性和强大的财务灵活性,以及强大的所有权结构,也是评级的重要因素。这些因素受到与集团快速扩张计划相关的执行风险、对监管和或有负债的暴露以及对行业普遍缺乏护士的担忧的制约。
The group has strengthened its position as a key player in the domestic private healthcare industry. As of September 2024, SHH operates three hospitals with 1,240 licensed beds (end-2023: 1,148 beds), capturing an estimated 7% of the market based on bed count. With two new hospitals opening from 4Q2024 and ongoing expansions, total bed capacity is expected to increase to around 1,900. This, along with strong industry growth drivers, will provide further upside to the group's operational and financial profiles. As of July 2024, SHH's patient throughput reached 741,000 and is on track to surpass the 1.2 million visits recorded in 2023.
该集团已经巩固了自己作为国内私人医疗行业关键参与者的地位。截至2024年9月,SHH运营着三家医院,拥有1,240张获得许可的病床(2023年年底:1,148张),根据床位数量占据约7%的市场份额。随着两家新医院在2024年第四季度开业及正在进行的扩张,总床位容量预计将增加到约1,900张。再加上强劲的行业增长驱动力,将进一步提升集团的运营和财务形象。截至2024年7月,SHH的患者流量达到741,000,预计将超过2023年录得的120万次访问。
Revenue for 2024 is likely to chart higher than the RM1.5 billion posted in 2023 based on strong 9M2024 results. The solid top-line performance has supported EBITDA growth and strong cash generation. The group projects to generate RM480 million to RM1.2 billion of annual cash flow from operations between 2025 and 2030, supported by portfolio growth.
2024年的营业收入预计将高于2023年的15亿马币,基于2024年前三季度强劲的业绩。稳健的顶线表现支持了EBITDA的增长和强劲的现金生成。该集团预计在2025年至2030年间每年从运营中产生48000万至12亿马币的现金流,支持组合的增长。
As at end-September 2024, SHH's borrowings stood at RM1.3 billion, with a debt-to-equity ratio of 0.45x. This is expected to decline slightly by year end to about RM1.0 billion following a scheduled debt repayment of approximately RM282 million. SHH forecasts borrowings in the range of between RM1.1 billion and RM1.7 billion from FY2025 to FY2030, with proceeds primarily funding the group's ongoing expansion plans. MARC Ratings believes the group's cash-generative operations will support the higher debt levels. Under the rating agency's sensitised case, which includes profitability stress, cash flow coverage on interest and debt is expected to remain strong at 7.9x-12.2x and 0.3x-0.4x over the forecast period.
截至2024年9月底,SHH的借款为13亿马币,债务与股本比率为0.45x。预计到年底略微下降至约10亿马币,原因是计划还款约为28200万马币。SHH预测2025至2030财年间的借款区间为11亿至17亿马币,资金主要用于支持集团持续的扩张计划。MARC评级认为,该集团现金生成的运营将支持更高的债务水平。在评级机构的敏感情形下,包括盈利能力压力,利息和债务的现金流覆盖预计在预测期内维持在7.9x-12.2x和0.3x-0.4x。